Insmed CEO Will Lewis on Rare Disease Pipeline, Drug Launches, and Expansion

Insmed's Rare Disease Drug Pipeline and Launches

• 💡 Insmed CEO Will Lewis discusses the company's rare disease drug pipeline, highlighting two key drugs: Arikayce for refractory non-tuberculosis mycobacterial lung disease and brensutriib for non-cystic fibrosis bronchiectasis.
• 🚀 Brensubriib has shown a strong launch, addressing over 9,000 patients and generating $144.6 million in preliminary fourth-quarter revenue, surpassing the first-year launch performance of Dupixent.
• ✅ Arikayce also exceeded raised guidance for 2025, demonstrating robust commercial performance.

Expanding Drug Indications and Market Potential

• 🔬 The Encore trial for Arikayce, targeting a frontline indication for MAC lung disease, is expected to read out in March or April, potentially expanding its addressable market from 30,000 to over 200,000 patients.
• 📈 If successful, this expanded indication for Arikayce, for which nothing is currently approved, could lead to substantial revenue growth, building on the projected $450-$470 million in 2025 revenue.
• 🎯 Brensubriib is also being investigated for hydroaenitis suppurativa (HS), a skin disease, with Phase 2 data anticipated in the second quarter of this year.

International Growth and Business Development

• 🌍 International sales, particularly in Japan, have been a significant driver of growth, with the team performing exceptionally well.
• 🇯🇵 Japan is still in the early stages of launch for Arikayce, with brensubriib expected to receive approval in the second half of the year, indicating strong future potential.
• 🤝 Insmed is actively pursuing business development opportunities, including the acquisition of INS1148, a monoclonal antibody targeting a specific stem cell factor, for potential indications in moderate to severe asthma and interstitial lung disease.
• 🚀 The company is focused on both internal pipeline development and external additions, signaling a period of significant activity and growth for Insmed.